The results showed that YK01 inhibited the BCL6BTB/SMRT interaction and reactivated BCL6 target genes in a concentration-dependent manner, and YK01 inhibited GBM cell growth in vitro and in vivo. The gene discussed is BCL6; the disease is glioblastoma.